Valuation Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 232.51 USD | -0.90% |
|
+1.40% | +16.56% |
| Jul. 29 | Align Technology to add directors, launch review after deal with Elliott | RE |
| Jul. 20 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 11,301 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 12.75% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 13,115 | 12,686 | 12,305 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 9.78% | -3.27% | -3.01% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 38.3x | 25.6x | 23.6x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 3.43x | 3.06x | 2.78x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.5x | 2.71x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.94x | 2.88x | 2.76x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 3.41x | 3.24x | 3x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 13.2x | 12x | 11x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 16.2x | 14.4x | 13x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 25.5x | 20.4x | 39.1x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 3.93% | 4.9% | 2.56% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.131 | 9.153 | 9.949 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,850 | 3,921 | 4,096 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 990.4 | 1,053 | 1,120 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 811.4 | 882.4 | 947.5 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.3 | 447 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,814 | 1,385 | 1,004 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 234.62 | 234.62 | 234.62 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/19/25 | 2/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 38.27x | 3.41x | 13.24x | -.--% | 11.3B | |
| 33.3x | 5.98x | 17.78x | 0.97% | 49.37B | |
| 30.78x | 3.07x | 13.23x | -.--% | 39.14B | |
| -23.98x | 360.64x | -22.03x | -.--% | 40.85B | |
| 47.84x | 4.86x | 31.45x | -.--% | 35.81B | |
| 28.91x | 8.36x | 21x | 0.4% | 30.5B | |
| 32.89x | 5.38x | 24.44x | -.--% | 16.14B | |
| 24.95x | 1.89x | 11.46x | -.--% | 12.77B | |
| 22.82x | 2x | 8.65x | 1.16% | 13.71B | |
| Average | 26.20x | 43.95x | 13.25x | 0.28% | 27.73B | |
| Weighted average by Cap. | 24.27x | 63.12x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
